SM
GILD icon

SG3 Management’s Gilead Sciences GILD Stock Holding History

SG3 Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,500
Closed -$327K – 558
2022
Q1 		$327K Sell
5,500
-22,000
-80% -$1.41M 0.01% 681
2021
Q4 		$2M Buy
+27,500
New +$1.89M 0.04% 343
2021
Q3 		– Sell
-6,500
Closed -$457K – 1086
2021
Q2 		$448K Sell
6,500
-8,600
-57% -$574K 0.02% 675
2021
Q1 		$976K Buy
15,100
+4,100
+37% +$264K 0.02% 611
2020
Q4 		$641K Buy
11,000
+8,000
+267% +$483K 0.01% 673
2020
Q3 		$190K Buy
+3,000
New +$208K 0.01% 730

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SG3 Management's GILD Position: Q2 2022 in Review

SG3 Management sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 5,500 shares — an estimated $327K sold.

SG3 Management first reported a position in GILD in Q3 2020 and held it in 6 quarters. The position peaked at $2M in Q4 2021. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

  • SG3 Management reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 5,500 Gilead Sciences shares in Q2 2022, an estimated $327K.
  • SG3 Management first reported a position in Gilead Sciences in Q3 2020 and held it in 6 quarters.
  • SG3 Management's Gilead Sciences position peaked at $2M in Q4 2021.
  • 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.